NPY2R
Basic information
Region (hg38): 4:155208636-155217078
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NPY2R gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 5 | |||||
missense | 12 | 15 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 12 | 4 | 4 |
Variants in NPY2R
This is a list of pathogenic ClinVar variants found in the NPY2R region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-155213977-C-G | not specified | Uncertain significance (Mar 20, 2024) | ||
4-155214003-T-C | Likely benign (Jul 10, 2018) | |||
4-155214016-C-A | not specified | Uncertain significance (Feb 12, 2024) | ||
4-155214054-G-C | not specified | Uncertain significance (Mar 23, 2022) | ||
4-155214098-C-T | Benign (Aug 21, 2018) | |||
4-155214136-T-C | not specified | Uncertain significance (Jan 17, 2023) | ||
4-155214267-T-C | not specified | Uncertain significance (Oct 22, 2021) | ||
4-155214305-G-A | Likely benign (Jun 05, 2018) | |||
4-155214382-G-A | not specified | Uncertain significance (Aug 31, 2022) | ||
4-155214433-G-A | not specified | Uncertain significance (Jun 27, 2022) | ||
4-155214453-G-A | Benign (Mar 01, 2018) | |||
4-155214489-G-A | not specified | Uncertain significance (Aug 28, 2023) | ||
4-155214537-A-T | not specified | Uncertain significance (Dec 06, 2022) | ||
4-155214578-C-A | not specified | Uncertain significance (Jul 20, 2021) | ||
4-155214593-C-G | Benign (Mar 29, 2018) | |||
4-155214661-G-A | not specified | Uncertain significance (Jun 16, 2024) | ||
4-155214850-A-G | not specified | Uncertain significance (Jan 30, 2024) | ||
4-155214917-C-T | Benign (Jun 08, 2018) | |||
4-155214973-G-A | Likely benign (Jul 04, 2018) | |||
4-155214986-T-G | not specified | Uncertain significance (Jun 10, 2024) | ||
4-155215046-T-G | not specified | Uncertain significance (Feb 03, 2023) | ||
4-155215049-C-A | Likely benign (Jul 16, 2018) | |||
4-155215050-C-A | not specified | Uncertain significance (Dec 21, 2022) | ||
4-155215074-A-G | not specified | Uncertain significance (Apr 12, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NPY2R | protein_coding | protein_coding | ENST00000329476 | 1 | 8450 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0355 | 0.932 | 125731 | 0 | 16 | 125747 | 0.0000636 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.812 | 178 | 211 | 0.843 | 0.0000112 | 2496 |
Missense in Polyphen | 51 | 80.009 | 0.63743 | 961 | ||
Synonymous | -1.28 | 101 | 85.9 | 1.18 | 0.00000471 | 786 |
Loss of Function | 1.85 | 4 | 10.5 | 0.383 | 6.16e-7 | 120 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000152 | 0.000152 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000792 | 0.0000791 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000653 | 0.0000653 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu- 31, Pro-34] NPY > PP, [Pro-34] PYY and NPY free acid.;
- Pathway
- Neuroactive ligand-receptor interaction - Homo sapiens (human);Sympathetic Nerve Pathway (Neuroeffector Junction);Peptide GPCRs;GPCRs, Class A Rhodopsin-like;Signaling by GPCR;Signal Transduction;Peptide ligand-binding receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;G alpha (i) signalling events;GPCR downstream signalling
(Consensus)
Recessive Scores
- pRec
- 0.158
Intolerance Scores
- loftool
- rvis_EVS
- -0.58
- rvis_percentile_EVS
- 18.59
Haploinsufficiency Scores
- pHI
- 0.284
- hipred
- Y
- hipred_score
- 0.604
- ghis
- 0.485
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.170
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Npy2r
- Phenotype
- growth/size/body region phenotype; taste/olfaction phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; skeleton phenotype; renal/urinary system phenotype; liver/biliary system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); immune system phenotype;
Gene ontology
- Biological process
- behavioral fear response;positive regulation of peptide secretion;outflow tract morphogenesis;cardiac left ventricle morphogenesis;G protein-coupled receptor signaling pathway;adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway;positive regulation of cytosolic calcium ion concentration;neuropeptide signaling pathway;nitric oxide mediated signal transduction;aging;locomotory behavior;positive regulation of cell-substrate adhesion;positive regulation of dopamine secretion;negative regulation of cAMP-mediated signaling;positive regulation of smooth muscle contraction;positive regulation of circadian sleep/wake cycle, non-REM sleep;secretion;negative regulation of secretion;regulation of sensory perception of pain;negative regulation of synaptic transmission, glutamatergic;negative regulation of excitatory postsynaptic potential;negative regulation of feeding behavior
- Cellular component
- plasma membrane;integral component of plasma membrane;non-motile cilium
- Molecular function
- peptide YY receptor activity;neuropeptide Y receptor activity;calcium channel regulator activity;protein binding;signaling receptor activity